The following message was updated on 7/12/2021 11:45:24 AM.
Could be game over for KVD900
KalVista's KVD900 is for administration only AFTER an attack occurs. With oral orladeyo (BCRX) taking over the oral prophylactic market there may be little to no need for KVD900 in the future. Perhaps it can be a backup for those few attacks that make it through Orladeyo treatment (<5%?) KVD824 (HAE prophylactic drug) has not even begun phase 2 trials yet. GAME OVER!!